core temperature were seen when the first melatonin treatment was given approximately 2 h after the temperature acrophase. These results indicate that melatonin was able to phase shift sleep and core temperature but was unable to synchronize core temperature consistently. In the majority of subjects, the sleepwake cycle could be synchronized.
Abstract In humans, the pineal hormone melatonin can phase shift a number of circadian rhythms (e.g., "fatigue," endogenous melatonin, core body temperature) together with the timing of prolactin secretion. It is uncertain, however, whether melatonin can fully entrain all human circadian rhythms. In this study, the authors investigated the effects of daily melatonin administration on sighted individuals kept in continuous very dim light. A total of 10 normal, healthy males were maintained in two separate groups in partial temporal isolation under constant dim light (< 8 lux) with attenuated sound and ambient temperature variations but with knowledge of clock time for two periods of 30 days. In these circumstances, the majority of individuals free run with a mean period of 24.3 h. In a double-blind, randomized crossover design, subjects received 5 mg melatonin at 20:00 h on Days 1 to 15 (Melatonin 1st) followed by placebo on Days 16 to 30 (Placebo 2nd) or vice versa (Placebo 1st, Melatonin 2nd) during Leg 1 with treatment reversed in Leg 2. The variables measured were melatonin (as 6sulphatoxymelatonin), rectal temperature, activity, and sleep (actigraphy and logs). In the experiment, 9 of the 10 subjects free ran with Placebo 1st, whereas Melatonin 1st stabilized the sleep-wake cycle to 24 h in 8 of 10 individuals. In addition, 2 individuals showed irregular sleep with this treatment. In some subjects, there was a shortening of the period of the temperature rhythm without synchronization. Melatonin 2nd induced phase advances (5 of 9 subjects), phase delays (2 of 9 subjects), and stabilization (2 of 9 subjects) of the sleep-wake cycle with subsequent synchronization to 24 h in the majority of individuals (7 of 9). Temperature continued to free run in 4 subjects. Maximum phase advances in INTRODUCTION In humans, the pineal hormone melatonin can phase shift a number of circadian rhythms (e.g., &dquo;fatigue,&dquo; endogenous melatonin, core body temperature) together with the timing of prolactin secretion (Arendt et al., 1984 (Arendt et al., , 1985 Deacon et al., 1994; Sack et al., 1987 Sack et al., , 1991 Wright et al., 1986) . A human phase response curve (PRC) using endogenous melatonin as a phase marker has been described in two reports (Lewy et al., 1992; Zaidan et al., 1994) . Its effects are dose related over the range of 0.05 to 5 mg; acute administration of 5 mg at 17:00 h is more effective at phase advance than are lower doses (Deacon and Arendt, 1995) . It remains questionable, however, whether melatonin can fully entrain all human circadian rhythms. Probably the best examples are found in the investigation of the effects of melatonin in blind people. Daily administration to 1 free-running blind man, exposed to all ambient time cues with the exception of the light:dark (LD) cycle, stabilized his sleepwake cycle, especially sleep onset, but failed to entrain endogenous melatonin, cortisol, or core body temperature rhythms Folkard et al., 1990 ). Subsequent reports have indicated that in many visually impaired people, melatonin can stabilize the sleep-wake cycle (e.g., Jan et al., 1994; Sack et al.,1991; Tzischinsky et al., 1992) , but only 1 individual has shown possible entrainment of a strongly endogenous rhythm such as melatonin (Sack et al., 1991) . In a preliminary report, Lewy and coworkers have suggestive evidence for entrainment of a free-running sighted individual (McArthur et al., 1995) . However, inspection of their data suggests that they shortened tau rather than inducing full synchronization.
Within the framework of an investigation into the properties of melatonin, we studied the effects of daily melatonin administration to sighted individuals kept in continuous very dim light and knowledge of clock time. The study protocol and conditions were designed to allow timed treatments under free-running conditions. In these circumstances, the majority of individuals free run with a mean tau of 24.3 h (Middleton et al., 1996a) .
MATERIALS AND METHODS

Subjects
A total of 10 normal subjects were recruited from male soldiers stationed at Famborough, United Kingdom. All subjects were healthy, taking no medication except for minor analgesics, and were ages 23.90 ± 0.75 years. Prior to the experiment, subjects were screened for normal amplitude and timing of melatonin production with reference to in-house laboratory values.
Round-the-clock urine collections were made with samples taken every 4 h and overnight. Excretion rates of 6-sulphatoxymelatonin (aMT6s, the major metabolite of melatonin) were measured by radioimmunoassay (RIA) . Each individual's dim light melatonin onset was determined by taking half-hourly blood samples between 19:00 and 02:00 h in lighting conditions < 50 lux. Plasma melatonin levels were determined by RIA (Fraser et al., 1983) , and onset time was calculated as the time at which plasma melatonin levels reached values twice the level of the assay limit of detection (5 pg/ml). Subjects were considered suitable for inclusion in the experiment if the plasma dim light melatonin onset fell between 21:00 and 24:00 h and if 24-h aMT6s output was within the normal range (12.81 ± 9.6 Jlg/24 h, n = 177) with acrophase times between 02:00 and 06:00 h. All individuals screened satisfied these requirements and participated in both legs of the study All subjects gave informed written consent, and the study protocol was approved by the Army Personnel Establishment Ethical Committee.
General Conditions
The subjects were maintained in two groups of 6 and 4 individuals in partial environmental isolation. The general experimental conditions have been described elsewhere (Middleton et al.,1996a) . Briefly, the unit consists of a large communal sleeping room with partially screened beds, a fully equipped kitchen, a computer room for performance testing, a room for watching videos, and an ablution area with a shower and toilet for each individual together with exercise machines. Air-conditioning ensured a temperature range of 21 to 29°C (mean = 22.5 ± 1.26°C), and sound was attenuated. The entire area was light tight, and illumination was provided by overhead banks of full spectrum lights (Osram Biolux) and diffusers (Siemens Lighting Ltd.) to give uniform light levels throughout the unit. Average light intensity at eye level could be controlled over the range of 0 to 2000 lux. Dim light (L:L, mean = 4.09 ± 0.80 lux) was imposed after an initial 24-h acclimatization period (lights on 07:00-23:00 h, approximately 500 lux). The experiments were conducted between September and March with a minimum of 6 weeks between legs.
Contact with experimenters was intermittent and random. A digital clock recording real time was present in the kitchen area. Food was self-selected and cooked by the subjects from a broad range of fresh and frozen ingredients and ready-prepared microwavable meals. Subjects were under observation 24 h a day to note compliance, and voice contact could be made at any time via an intercom. Subjects were instructed to eat and sleep when they wished and never were disturbed when sleeping. Initial experiments suggested that when subjects were aware of the impending end of an experiment, they attempted to force themselves into synchrony with 24 h in preparation for release. In consequence, they were not informed of the precise length of the experiment but were told the maximum time period would be 33 days. In these conditions, subjects in our previous experiments showed freerunning rhythms that differed significantly from 24 h within 10 days of the start of dim light (Middleton et al., 1996a) .
Treatment
The light intensity throughout the unit was maintained at 4.09 ± 0.8 lux for the duration of the experiment (30 days each leg). The subjects took coded pills every 8 h (12:00, 20:00, and 04:00 h) when awake. Capsules taken at 12:00 and 04:00 h always were placebos. In a double-blind, randomized crossover design, they received melatonin (5 mg in gelatin lactose, Penn Pharmaceuticals Ltd., Tredegar, United Kingdom) in the 2000-h capsule for the first 15 days (Melatonin 1st) and placebo (gelatin lactose) for the second 15 days of the study (Placebo 2nd) or vice versa (Placebo lst, Melatonin 2nd). In a second leg, the treatment order was reversed.
Sample Collection and Recording
Throughout the experiments, except when showering and defecating, core body temperature (T) was monitored continuously by means of a rectal probe connected to a Grant memory Logger (Grant Instruments Ltd., Cambridge, United Kingdom) recording every 6 min. Activity (A) was logged every 20 sec by means of wrist-mounted accelerometers (Mini-Motionloggers, Ambulatory Monitoring Inc., New York). All urine passed over 4-hour intervals or during the sleep period was collected and measured, and an aliquot was frozen for measurement of aMT6s, the major metabolite of melatonin. The subjects kept daily sleep diaries recording bedtime, latency, number and duration of night awakenings, wake-up time, and sleep quality. In a similar manner, they recorded their main activities, including meals and drinks, at halfhour intervals during each 24-h period.
Analysis
Urinary aMT6s levels were measured by RIA , and the excretion rate (nanograms /hour) and total excretion per 24 h (micrograms) were calculated. Temperature data were edited to remove values below 36°C and readings associated with showers or exercise. The data were then demasked. Activity, temperature readings, and aMT6s excretion rates were subjected to 3-day moving-window cosinor analysis (Minors and Waterhouse, 1988 ) and spectral analysis using Action3 software (Ambulatory Monitoring Inc.). This method of analysis describes time-series data in terms of the power at each of a range of underlying frequencies. Under our experimental conditions, the spectral peak would be expected to fall between 23 and 25 h. The range of frequencies investigated was 0 to 36 h, and the time of the highest peak was considered to be the period of the data under analysis.
Acrophase times determined by cosinor analysis were further assessed by linear regression with day as the independent variable to determine individual periods (tau = 't) over the study period. Only data with significant fits (p::;; .05) and percentage rhythms > 70% for temperature and aMT6s and > 40% for activity were used (100% = all points falling on the calculated curve). During melatonin treatment, urinary aMT6s derived from exogenous melatonin completely masked the endogenous profile, and no cosinor analysis was performed on aMT6s for these sections. Automatic sleep scoring of manually tagged &dquo;in bed&dquo; intervals was carried out using Action3 software. The &dquo;in bed&dquo; intervals were marked using the event marking of the activity recordings and by eye from the activity trace. They were then confirmed by reference to the sleep logs and activity diaries.
Sleep onset and offset times for each individual also were assessed by linear regression analysis and spectral analysis to determine tau.
I7emasking of Core Body Temperature
The method used was based on that described by Folkard (1988 Folkard ( , 1989 . Temperature data from 6-min readings were binned into hourly intervals after editing to remove raised values due to exercise and low-ered values due to incorrect wearing of the probes. Two factors were then taken into account: the effects of sleep and the effects of melatonin administration.
Sleep-Wake Cycle
In the case of sleep, the following approach was used. Given that there can be wide individual differences in the effects of masking, we determined individual correction factors for sleep. For this, we calculated the mean hourly temperature for the first 3 days of placebo administration when this was the first treatment and calculated the differences from normalized demasked hourly temperature values supplied by S. Folkard (Body Rhythms and Shiftwork Centre, University of Wales, Swansea, United Kingdom) (Folkard, 1988 (Folkard, , 1989 . These values were then used to correct the masked data. The normalized demasked hourly temperature values are expressed for each hour after wake-up and then for each hour after sleep onset for 8 h sleep in 24 h.
However, in this series of experiments, sleep frequently was longer than the 8 h used to determine the average correction factors. To take this into consideration, we assumed that for a sleep period in excess of 8 h, temperature would not be suppressed more than the maximum with an 8-h sleep period and similarly that temperature would not be increased more than the maximum found over a 16-h wake period. The correction factor profile was proportionally expanded to cover the length of sleep or wake present, and hourly correction values were determined by interpolation. For sleep and wake periods shorter than 8 and 16 h, respectively, the correction factors were applied directly. Apart from subjects showing irregular sleep (Subjects 2 and 5), the sleep periods ranged between 5 and 12 h and the wake periods between 9 and 22 h in length.
Melatonin Administration
Differences in the mean hourly temperature data for the first 3 days of placebo and for the first 3 days of melatonin administration (in each case when these were the first treatments given) were obtained for each subject and used to correct the masked data.
Repeated measures analysis of variance (ANOVA) followed by Duncan's multiple range post hoc test were used to evaluate any differences in acrophase times derived from the masked and demasked data.
One-way ANOVA was used to estimate differences in tau derived from the different analyses.
Linear regression analysis and spectral analysis were carried out on individual and mean grouped activity, temperature and aMT6s acrophase times, and sleep onset and offset times. Grouped mean data were further analyzed by repeated measures ANOVA.
RESULTS
Compliance
Subject 2 withdrew during the Placebo lst, Melatonin 2nd leg, and Subject 6 withdrew during Placebo 2nd treatment in both cases for family reasons. Subject 5 had problems with the rectal probe during the Placebo lst, Melatonin 2nd leg, and so insufficient data were present for analysis, and Subject 9 had a faulty temperature logger during the initial days of Placebo lst.
Overall, mean percentages of 75.9 ± 2.9%, 92.0 ± 1.6%, 95.6 ± 1.2%, and 88.7 ± 2.4% of the theoretical amounts of data for T, A, sleep, and aMT6s, respectively, were present.
Temperature Analysis
There were very few significant differences between tau derived from masked and demasked data.
However, because 2 individuals (Subjects 4 and 7) showed significant differences between masked and demasked temperature data on Placebo lst, Melatonin 2nd treatments, and because 3 showed differences on a single treatment (Subject 1: Placebo lst; Subject 6: Melatonin 2nd; Subject 8: Melatonin 2nd), the demasked data, individually corrected for sleep and (where appropriate) melatonin, were retained for discussion. Activity, Sleep, and Temperature Inspection of the individual records (as plotted in Fig. 1 ) and reference to the calculated periodicities showed that 9 of 10 subjects free ran under Placebo 1st by our criteria; that is, the period calculated by linear regression analysis of acrophase times or sleep onset and offset times was greater than 24 h (p < .05), and 95% confidence limits do not encompass 24 h. The Melatonin 1st treatment stabilized the sleep-wake cycle to 24 h in 8 of 10 individuals; however, 2 of 10 showed highly irregular sleep during the entire period of melatonin treatment. Crossover to placebo in these 2 subjects, and also to the Placebo 1st treatment, was accompanied by a reasonably consolidated sleep-wake cycle. The Melatonin 2nd treatment induced phase advances (5 of 9 subjects), phase delays (2 of 9 subjects), and stabilization (2 of 9 subjects) of the rest activity cycle with subsequent synchronization to 24 h in the majority of individuals. However, 1 subject (Subject 7) who delayed and synchronized with melatonin treatment subsequently desynchronized with a rapid second phase delay. Figure 1 shows examples of stabilization of sleep-wake to 24 h with Melatonin 1st in Subject 8 (Panel A), irregular sleep with Melatonin 1st in Subject 2 (Panel B), phase advance with Melatonin 2nd in Subject 3 (Panel C), phase delay with Melatonin 2nd in Subject 6 (Panel D), and double phase delay with Melatonin 2nd in Subject 7 (Panel E). Table 1 shows the individual periods derived from cosinor and spectral analyses for each of the variables in each of the treatments. Synchronization was considered to be present when the periodicity derived by regression analysis of cosinor-derived parameters was not significantly different from 24 h. In the case of temperature, both phase advances and phase delays were initially induced by melatonin treatment. With Melatonin lst, 8 of 10 subjects appeared to be synchronized by melatonin, although a shortening of tau without synchronization to 24 h also is a possible interpretation. With Melatonin 2nd, 3 subjects continued to free run with shortened tau and 1 did so with lengthened tau compared to placebo. There were no overall differences in temperature amplitude with treatment on analysis of individual demasked temperature data by repeated measures ANOVA.
In view of the heterogeneous nature of the response to melatonin and the different circadian times (CTs) on the day of initial melatonin treatment, overall grouping of the data was considered inappropriate. Thus, group means for sleep onset, sleep offset, activity acrophase, and temperature acrophase were derived from the 6 subjects (Subjects 1, 3, 4, 8, 9, and 10) who did not show either irregular sleep (Subjects 2 and 5) or phase delay with Melatonin 2nd (Subjects 6 and 7). These are illustrated in Fig. 2 . Analysis of variance indicated a significant difference between the treatments on the Placebo lst, Melatonin 2nd leg (p = .002) and a trend to a difference between the treatments on the Melatonin lst, Placebo 2nd leg (p = .06) whereby both sleep time and temperature were not different from 24 h with melatonin treatment but free ran with placebo treatment. Comparison of treatments Placebo lst and Melatonin 1st showed a significant difference for sleep onset, sleep offset, activity acrophase, and temperature acrophase by ANOVA (p < .001). ANOVAbetween Placebo 2nd and Melatonin 2nd showed a significant difference in activity and temperature acrophase times (p < .001) but no significant difference in sleep onset or offset times.
It would be wrong to conclude that temperature (or, indeed, the sleep-wake cycle) was in fact fully synchronized in all of these individuals under melatonin treatment. Temperature provides clearer data, and regression analysis indicated that Subjects 3 and 8 had taus shorter than 24 h with melatonin treatment, whereas Subject 4 had a tau on melatonin shorter than placebo but that nevertheless was free running (Fig. 3 ).
Because CT of administration is the most obvious explanation for these different responses, we investigated the relationship of the time of the Melatonin 2nd treatment relative to calculated core body temperature maximum on the previous day. The 2 subjects who delayed with Melatonin 2nd received their first melatonin treatment 5.15 and 6.20 h before temperature maximum, a substantial delay of their temperature rhythms relative to all other subjects who were treated from 4.28 h before to 1.14 h after maximum T. In view of these relationships, we calculated a PRC for the phase shift in temperature induced by treatment with melatonin from the temperature acrophases on Days 15 and 16 of the study. These data (from 8 subjects) are shown in Fig. 4 , where it can be seen that a maximum phase advance is present when treatment is close to maximum T. Calculation of maximum T prior to Melatonin lst is less reliable because only 1 day of data was available prior to treatment. However the data from Days 1 and 2 of the study also are shown in Fig. 4 . The melatonin treatment time is shown relative to temperature acrophase (hours) and also as circadian phase (degrees), where 0° is the calculated temperature nadir (Jewett et al., 1994) . aMT6s During placebo treatment, aMT6s free ran in all subjects with Placebo lst, Melatonin 2nd. In 5 of 9 subjects, aMT6s free ran with Placebo 2nd. Table 2 shows the mean endogenous aMT6s per 24 h for each subject. The periodicity was closely coupled to that of temperature (r = .63, p = .02), and there were no significant differences in amplitude by repeated measures ANOVA in the course of treatment. The endogenous secretion in all subjects was within the normal range for age (13.14 ± 9.8 ~Lg/24 h to 54.0 ± 6.0 Jlg/24 h), and there were no obvious differences in endogenous secretion in relation to the responses ob- (Table 2 ). The excretion of aMT6s during melatonin treatment first indicated compliance (97.4 ± 0.6%) and also provided an estimate of individual clearance (Table 2 ). There were no apparent relationships between excretion of aMT6s and response with the exception of 1 subject (Subject 1), who had delayed NOTE: aMT6s = 6-sulphatoxymelatonin. *Tau significantly different to 24 h (p < .05); upper and lower limits at 95% do not encompass 24:00 h. clearance as indicated by a return to endogenous levels 5 days after cessation of treatment compared to 48 h (group mean) after stopping treatment in all other subjects. It is of interest to note (Table 1) that this subject had a substantially shorter tau when placebo was administered after melatonin than when placebo was administered first.
DISCUSSION
The dose of melatonin used in this study has been used extensively in the treatment of rhythm-related sleep disorder (e.g., Arendt et al., 1987; Dahlitz et al., 1991; Jan et al., 1994) and in an acute dose-response study generated a larger phase shift than did more Figure 2 . Group means + standard errors derived from 6 subjects (Subjects 1, 3, 4, 8, 9, and 10) who did not show either irregular sleep or phase delay for all treatments: (A) activity acrophase, (B) temperature acrophase, (C) sleep onset time, (D) sleep offset time. physiological dose levels (Deacon and Arendt, 1995) . Thus, it would seem appropriate to investigate its more formal properties in partial isolation. It is clearly desirable, in view of the evidence for a PRC to melatonin, that its administration be timed according to individual circadian phase. In the present study, designed to investigate group effects, it was more practical and less disturbing to the subjects to keep the clock time of administration constant for all. The relationship to circadian phase could then be derived a posteriori following analysis of the temperature data.
The treatment time chosen was such that it was anticipated that it would fall in the phase advance window in the majority of subjects. In these experimental conditions, we have shown previously (Middleton et al., 1996a ) that subjects free run and do not synchronize as a group. Such was the case in the present study with placebo administration. This suggests that there were no strong social masking pressures to sleep or to be awake at particular times. The mathematical demasking procedures used for core temperature are not ideal, but the general approach used here has been Figure 3 . Regression analysis of demasked temperature acrophase times (Subjects 3, 4, and 8) showing a shortening of tau with melatonin treatment. In the case of Subj ect 8, tau was significantly shorter than 24 h. validated in both entrained and phase-shifted conditions with subjects sleeping at different circadian phases. (Folkard, 1988 (Folkard, , 1989 .
Taken on a daily basis from the 2nd day of partial environmental isolation in dim light, melatonin appears to maintain synchronization of the sleepwake/activity-rest cycle and core temperature in most individuals. The exception was the irregular sleep seen in 2 subjects. In Subjects 1 and 6, activity and temperature appeared to free run with Melatonin lst but with a shorter tau than with Placebo lst.
When melatonin is given after a period of free run, synchronization of sleep can take place by phase ad- Figure 4 . Phase response curve for melatonin using temperature as the phase marker. Closed circles represent data derived from subjects receiving melatonin (MT) as a second treatment after 15 days of placebo. Open circles represent data derived from melatonin given as a first treatment after 1 day in a normal light:dark cycle (lights off 23:00-07:00 h). Melatonin treatment times relative to temperature acrophase (hours) and circadian phase (degrees) are shown. vance when the administration time falls within around 3 h before to 4 h after maximum T. It is of interest to note that synchronization takes place over a period of days (Fig. 1 ), indicating that melatonin is not a strong and immediate sleep inducer. Although temperature appeared synchronized in 4 subjects within this group, detailed analysis suggests that tau may be shortened rather than synchronized. It is possible, in those subjects where tau for temperature was indistinguishable from 24 h, that a very slow free run was present but was not detectable in this length of data series. Such considerations also apply to the sleep-wake cycle. It is of interest to note that when placebo was given after a period of melatonin treatment, the recorded periodicity was shorter in 6 of 9 subjects than during the Placebo lst treatment (Table 1) . This suggests that melatonin can have aftereffects on endogenous periodicity.
The apparent synchronization of the sleep-wake cycle over a period of days by phase delay in Subject 6, and the partial synchronization in Subject 7 where Table 2 . Amounts of aMT6s excreted (micrograms). NOTE: aMT6s = 6-sulphatoxymelatonin. initial administration times were 5 to 6 h before maximum T, is less convincing (see Fig. 1D ,E). Subject 6 in particular, although having a tau of sleep onset not significantly different from 24 h under melatonin, nevertheless appears to have a shortened tau rather than entrainment. Subject 7 shows two clear phase delays and apparent short-term entrainment to melatonin administered shortly after sleep offset. There was no evidence for entrainment of temperature in either of these subjects, although there were phase shifts to the initial melatonin treatment. These subjects had long free-running periods. Indeed, this was the reason for melatonin administration falling within a phase delay window: the T rhythm had moved much farther than that of the other 8 subjects. It is conceivable that the limits of entrainment of the sleep-wake cycle by melatonin depend on individual tau such that a free run much longer (or possibly shorter) than 24 h is beyond the limits of entrainment. During melatonin administration in Subject 7 in particular, the temperature rhythm appeared to be unstable, and it is likely that the major phase shifts seen in the sleep-wake cycle are a result of this constantly changing phase. Possible short-term entrainment by melatonin at sleep offset in Subject 7 may be an artifact. However, if this phenomenon were to be observed in other subjects, then an explanation must be sought. Gillette and coworkers, using in vitro suprachiasmatic nucleus preparations, observed phase advances by melatonin at two CTs (McArthur et al., 1991) , and a possible mechanism may relate to this observation. Only a longer period of investigation in more subjects will resolve some of these questions.
According to the PRC of Lewy et al. (1992) , maximum phase advances to melatonin are seen within 5 to 8 h of evening melatonin onset (ca. 21:00 h = CT 14). This corresponds closely to the maximum phase advance seen in core temperature in relation to maximum T in these experiments and also is consistent with the PRC of Zaidan et al. (1994) .
The irregular sleep noted with Melatonin lst in 2 subjects was unexpected. These 2 subjects received melatonin 2.3 and 2.5 h after maximum T. In a normal environment, this would be expected to induce a phase advance. However, in a normal environment, the LD cycle and other time cues clearly will modify any such response, and the net result will be a combination of zeitgeber effects. Because of these observations, we performed a second small experiment designed to induce irregular sleep by administration of melatonin within 2 h of maximum T (Middleton et al., 1996b) . In this case, 2 of 6 subjects showed a similar phenomenon. In the present study, there may be an analogy with the &dquo;squashing&dquo; of the amplitude of T and cortisol and large phase jumps of the circadian system induced by bright light given at or very close to minimum T in a constant routine (Jewett et al., 1991) . It is conceivable that melatonin may provoke a similar response if suitably timed with respect to the sleep-wake cycle. Another explanation may be that if the sleep-wake cycle is governed by two oscillators (Wehr et al., 1993) , then melatonin may be able to uncouple such a system (Middleton et al., 1996b) . Whatever the explanation, it is clear that melatonin does not act as a conventional sleep-inducing drug. Moreover, it will be important for its therapeutic uses to investigate this phenomenon further given that the sleeping patterns observed would be highly undesirable in normal life. Different doses and formulations clearly must be investigated.
We conclude that, as discussed previously (Arendt et al., 1985) , melatonin has weak zeitgeber effects. It is able to phase shift sleep, its own rhythm, core temperature, and other rhythms. Most evidence indicates that it is rarely able to synchronize core temperature or, indeed, its own rhythm (Folkard et al., 1990; Sack et al., 1991) . Its effects on sleep suggest that, in some individuals, the sleep-wake cycle can be synchronized but that this may depend on a sufficiently short individual tau. Its differential effects on temperature and sleep suggest either different target control systems or a major contribution of acute temperature suppression, mild sleepiness, and lowered alertness at the appropriate circadian phase. Only further experimen-tation can resolve these questions. Combined with other time cues, however, it is clearly able to hasten adaptation to phase shift (Deacon and Arendt, 1996) .
